Crewe Advisors’s Regeneron Pharmaceuticals REGN Stock Holding History
Bought
Maintained
Sold
Other funds holding REGN
Crewe Advisors's REGN Position: Q2 2026 in Review
Crewe Advisors increased its Regeneron Pharmaceuticals (REGN) stake by 25% in Q2 2026, buying an estimated $1.36K and bringing the position to 10 shares worth $6.24K. The position accounts for ﹤0.01% of the portfolio, ranked #836.
Crewe Advisors first reported a position in REGN in Q3 2020 and has held it in 18 quarters since. The position peaked at $35K in Q3 2022. 1,332 funds tracked by Wall St. Rank hold REGN as of Q2 2026.
- Crewe Advisors held 10 shares of Regeneron Pharmaceuticals worth $6.24K as of Q2 2026.
- Crewe Advisors bought 2 Regeneron Pharmaceuticals shares in Q2 2026, an estimated $1.36K.
- Regeneron Pharmaceuticals made up ﹤0.01% of Crewe Advisors's portfolio in Q2 2026, its #836 holding.
- Crewe Advisors first reported a position in Regeneron Pharmaceuticals in Q3 2020 and has held it in 18 quarters since.
- Crewe Advisors's Regeneron Pharmaceuticals position peaked at $35K in Q3 2022.
- 1,332 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.
Based on Crewe Advisors's 13F filing for Q2 2026, filed 24 Jul 2026.